Lymphoid Nodules and Nodular Lymphoid Hyperplasia in Bone Marrow Biopsies

1985 ◽  
Vol 74 (1) ◽  
pp. 19-22 ◽  
Author(s):  
Roberto Navone ◽  
Mauro Valpreda ◽  
Achille Rich
Blood ◽  
1974 ◽  
Vol 43 (3) ◽  
pp. 389-400 ◽  
Author(s):  
Arkadi M. Rywlin ◽  
Rolando S. Ortega ◽  
Carlos J. Dominguez

Abstract A study of consecutive bone marrow aspirates from 365 patients without lymphoproliferative disorder, ten patients with chronic lymphocytic leukemia (CLL), and 25 patients with malignant lymphoma disclosed a clear separation of normal from abnormal lymphoid nodules (LN). Normal LN were found in 47% of patients and were classified into lymphoid follicles and lymphoid infiltrates. A new entity, nodular lymphoid hyperplasia (NLH), was diagnosed on ten bone marrows which contained a low-power field displaying four or more lymphoid nodules or showed a lymphoid nodule larger than 0.6 mm. The clinical significance of nodular lymphoid hyperplasia remains unknown; in certain cases it represents a precursor state of a mature lymphocytic lymphoproliferative disorder. Nodular aggregates in CLL are of the infiltrate type and exhibit a tendency to confluence. Eleven of the 25 patients with malignant lymphoma displayed lymphoreticular nodules which were cytologically similar to the original lymphoma and different from normal LN. Two patients, one with reticulum cell sarcoma and one with Hodgkin’s disease, showed NLH of the bone marrow. Bone marrow LN in patients with an established diagnosis of mature lymphocytic lymphoma have to be interpreted with the utmost caution. Confluence of LN, irregular shapes, and the presence of prolymphocytes and lymphoblasts speak for lymphomatous nodules. Additional clinicopathologic studies are necessary to sharpen the distinction between NLH and well-differentiated lymphoproliferative disorders.


2018 ◽  
Vol 40 (4) ◽  
pp. 332-335
Author(s):  
P V Kuzyk ◽  
M A Savchyna ◽  
S G Gychka

Aim: To describe the case of rare benign lymphoproliferative disorder — pulmonary nodular lymphoid hyperplasia in the patient with previous pulmonary tuberculosis. Materials and Methods: In the case of pulmonary nodular lymphoid hyperplasia clinical, laboratory, instrumental and morphological examination was performed. Results: 44-year-old woman in 7 years after successfully treated infiltrative drug-susceptible tuberculosis of the right lung, was hospitalized with a suspected tumor of the left lung root. The patient underwent left-sided pneumonectomy with lymph nodes dissection. The results of histopathological and immunohistochemical studies evidenced on nodular lymphoid hyperplasia of the left lung. Conclusion: Pulmonary nodular lymphoid hyperplasia is a rare lymphoproliferative disorder of the lung with favorable prognosis. For the purpose of differential diagnosis, it is necessary to apply immunohistochemistry.


2020 ◽  
Vol 37 (5) ◽  
pp. 424-430
Author(s):  
Paola Quarello ◽  
Maurizio Bianchi ◽  
Alessandro Gambella ◽  
Luca Molinaro ◽  
Elisa Tirtei ◽  
...  

1997 ◽  
Vol 31 (5) ◽  
pp. 582-585 ◽  
Author(s):  
Anna M Whitling ◽  
Pablo E Pérgola ◽  
John Lee Sang ◽  
Robert L Talbert

OBJECTIVE: TO report a case of agranulocytosis secondary to spironolactone in a patient with cryptogenic liver disease. CASE SUMMARY: A 58-year-old Hispanic woman with cryptogenic cirrhosis was admitted to University Hospital on October 31, 1995. Laboratory data revealed a leukocyte count of 1.0 × 103/mm3 and an absolute neutrophil count (ANC) of 10 cells/mm3. Prior to treatment with spironolactone, the leukocyte count was 10.2 × 103/mm3 and ANC 8400 cells/mm3. Agranulocytosis resolved 5 days following the discontinuation of spironolactone. Results from the bone marrow biopsies before and after treatment with spironolactone suggested that agranulocytosis was caused by the drug's toxic effect on the bone marrow. DISCUSSION: Drug-induced agranulocytosis is a serious adverse effect, occurring at a rate of approximately 6.2 cases per million persons each year. In addition to the case reported here, three other reports of agranulocytosis secondary to spironolactone have been published in the literature. Several factors have been identified that may increase a patient's risk for developing agranulocytosis, including increased age, hepatic or renal impairment, drag dosage and duration, and concurrent medications. CONCLUSIONS: Agranulocytosis secondary to spironolactone is a serious potential adverse effect. Patients with risk factors for developing this adverse effect should be closely monitored since early detection and discontinuation of spironolactone can improve prognosis.


2000 ◽  
Vol 95 (8) ◽  
pp. 2147-2149 ◽  
Author(s):  
Mounzer Samman ◽  
Marc J. Zuckerman ◽  
Arjun Mohandas ◽  
Joan T. Hoffpauir ◽  
Stanislaus Ting

Cancer ◽  
1980 ◽  
Vol 46 (1) ◽  
pp. 173-177 ◽  
Author(s):  
L. Patrick James ◽  
Sanford A. Stass ◽  
H. R. Schumacher

2012 ◽  
Vol 87 (7) ◽  
pp. 734-736 ◽  
Author(s):  
Anna Tasidou ◽  
Maria Roussou ◽  
Evangelos Terpos ◽  
Efstathios Kastritis ◽  
Maria Gkotzamanidou ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document